Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Abstract: Alzheimer’s disease (AD), a primary cause of dementia globally, is traditionally diagnosed via cerebrospinal fluid (CSF) measures and positron emission tomography (PET). The invasiveness, cost, and limited accessibility of these methods have led to exploring blood-based biomarkers as a promising alternative for AD diagnosis and monitoring. Recent advancements in sensitive immunoassays have identified potential blood-based biomarkers, such as Aβ42/Aβ40 ratios and phosphorylated tau (p-tau) species. This paper briefly evaluates the clinical utility and reliability of these biomarkers across various AD stages, highlighting challenges like refining plasma Aβ42/Aβ40 assays and enhancing the precision of p-tau, particularly p-tau181, p-tau217, and p-tau231. The discussion also covers other plasma biomarkers like neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and synaptic biomarkers, assessing their significance in AD diagnostics. The need for ongoing research and development of robust assays to match the performance of CSF and PET biomarkers is underscored. In summary, blood-based biomarkers are increasingly crucial in AD diagnosis, follow-up, prognostication, treatment response evaluation, and population screening, particularly in primary care settings. These developments are set to revolutionize AD diagnostics, offering earlier and more accessible detection and management options.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics ; volume:62 ; number:6 ; year:2024 ; pages:1063-1069 ; extent:07
Clinical chemistry and laboratory medicine ; 62, Heft 6 (2024), 1063-1069 (gesamt 07)
- Urheber
- DOI
-
10.1515/cclm-2023-1434
- URN
-
urn:nbn:de:101:1-2404291659004.545366523722
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Arslan, Burak
- Zetterberg, Henrik
- Ashton, Nicholas J.
Ähnliche Objekte (12)
Blood-based molecular biomarkers for Alzheimer’s disease
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration
Melatonin: A potential nighttime guardian against Alzheimer’s
Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease
Blood-based molecular biomarkers for Alzheimer’s disease
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration
Melatonin: A potential nighttime guardian against Alzheimer’s
Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease
Blood-based molecular biomarkers for Alzheimer’s disease
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration
Melatonin: A potential nighttime guardian against Alzheimer’s
Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease